Get the Stockscreener App
0.3094
1.78%
-0.0056
Renovaro Inc stock is traded at $0.3094, with a volume of 556.05K.
It is down -1.78% in the last 24 hours and down -13.98% over the past month.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
See More
Previous Close:
$0.315
Open:
$0.315
24h Volume:
556.05K
Relative Volume:
0.38
Market Cap:
$53.36M
Revenue:
-
Net Income/Loss:
$-41.23M
P/E Ratio:
-0.442
EPS:
-0.7
Net Cash Flow:
$-11.54M
1W Performance:
-5.32%
1M Performance:
-13.98%
6M Performance:
-59.10%
1Y Performance:
-78.95%
1-Day Range:
$0.3077
$0.3299
1-Week Range:
$0.3012
$0.34
52-Week Range:
$0.2755
$2.34
Renovaro Inc Stock (RENB) Company Profile
Name
Renovaro Inc
Sector
Industry
Phone
45 39179840
Address
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES
Compare RENB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RENB
Renovaro Inc
|
0.31 | 57.38M | 0 | -41.23M | -11.54M | -0.70 |
|
ONC
Beone Medicines Ltd Adr
|
246.64 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.63 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.57 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.51 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Renovaro Inc Stock (RENB) Latest News
What Analysts Think About Renovaro Inc (NASDAQ: RENB)’s Potential Raise - Stocksregister
Predictive Oncology says court denies Renovaro motion for expedited trial - TipRanks
Predictive Oncology to defend against Renovaro’s claims in court By Investing.com - Investing.com Canada
Predictive Oncology (POAI) Addresses Legal Dispute with Renovaro - GuruFocus
Court Denies Renovaro Motion for an Expedited Trial in July | POAI Stock News - GuruFocus
Court Denies Renovaro Motion for an Expedited Trial in July - GlobeNewswire
Delaware Court Rejects Renovaro's Rush to Trial Against Predictive Oncology, Cites Critical Delays - Stock Titan
Renovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology Merger - MSN
Predictive Oncology Stock Hits 1-Month Low Amid Renovaro Legal Clash, But Retail Leans Bullish By Stocktwits - Investing.com India
Major Moves And Shakes In Health Care Sector - Finimize
UPDATERenovaro Inc. Announces Expedited Trial for 2025 Lawsui - GuruFocus
Court Fast-Tracks Renovaro's Lawsuit to Force Merger After Predictive Oncology's $545K Securities Breach - Stock Titan
Renovaro Sues Predictive Oncology (POAI) Over Merger Agreement D - GuruFocus
Renovaro Gets Expedited Trial in Predictive Oncology Merger Dispute - marketscreener.com
Renovaro announces expedited trial on suit to enforce Predictive Oncology merger - TipRanks
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology - The Manila Times
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology | RENB Stock News - GuruFocus
Renovaro Inc. Secures Ruling to Expedite Trial Against Predictive Oncology Over Breach of Merger Agreement - Nasdaq
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to - GlobeNewswire
Court Fast-Tracks Renovaro's Lawsuit to Force Predictive Oncology Merger After 50% Stock Jump Drama - Stock Titan
RENB Stock Touches 52-Week Low at $0.28 Amid Market Challenges - Investing.com Australia
The Manufacturers Life Insurance Company Makes New $38,000 Investment in Renovaro Inc. (NASDAQ:RENB) - Defense World
Voya Investment Management LLC Acquires Shares of 35,312 Renovaro Inc. (NASDAQ:RENB) - Defense World
Renovaro launches AI platform to advance neurology drug discovery By Investing.com - Investing.com Nigeria
Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform - GlobeNewswire
Renovaro Launches Augusta, an AI-Powered Precision Neurology Pla - GuruFocus
Renovaro Inc. (NASDAQ:RENB) Shares Acquired by Barclays PLC - Defense World
Renovaro (REN) Unveils Augusta: A Breakthrough in Precision Neurology | RENB Stock News - GuruFocus
Renovaro BioSciences launches Augusta AI-powered precision neurology platform - TipRanks
Renovaro (REN) Unveils Augusta: A Breakthrough in Precision Neur - GuruFocus
Renovaro launches AI platform to advance neurology drug discovery - Investing.com
Renovaro BioSciences, Amsterdam UMC enter collaboration agreement - TipRanks
Renovaro Inc. (NASDAQ:RENB) Shares Acquired by Wells Fargo & Company MN - Defense World
Renovaro partners with Amsterdam UMC on cancer diagnostics - Investing.com
Renovaro and Amsterdam University Medical Center Announce Exclus - GuruFocus
Renovaro partners with Amsterdam UMC on cancer diagnostics By Investing.com - Investing.com India
Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics - The Manila Times
Renovaro Inc. and Amsterdam UMC Enter Exclusive Collaboration to Develop Blood Platelet RNA Diagnostics - Nasdaq
Renovaro and Amsterdam University Medical Center Announce - GlobeNewswire
Biotech Tells Chancery Drug Co. Abused Merger Prospects - Law360
Renovaro Inc. (NASDAQ:RENB) Shares Acquired by JPMorgan Chase & Co. - Defense World
Renovaro Inc Stock (RENB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Renovaro Inc Stock (RENB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| William Anderson Wittekind | 10% Owner |
Jul 17 '24 |
Sale |
1.46 |
16,362 |
23,889 |
841,433 |
| William Anderson Wittekind | 10% Owner |
Jul 15 '24 |
Sale |
1.41 |
21,954 |
30,955 |
875,795 |
| William Anderson Wittekind | 10% Owner |
Jul 10 '24 |
Sale |
1.51 |
75,000 |
113,250 |
894,645 |
| William Anderson Wittekind | 10% Owner |
Jul 11 '24 |
Sale |
1.51 |
14,896 |
22,493 |
897,749 |
| William Anderson Wittekind | 10% Owner |
Jul 09 '24 |
Sale |
1.53 |
4,630 |
7,084 |
969,645 |
| William Anderson Wittekind | 10% Owner |
Jul 05 '24 |
Sale |
1.55 |
60,000 |
93,000 |
974,275 |
| William Anderson Wittekind | 10% Owner |
Jul 03 '24 |
Sale |
1.51 |
50,000 |
75,500 |
1,034,275 |
| William Anderson Wittekind | 10% Owner |
Jul 01 '24 |
Sale |
1.56 |
60,000 |
93,600 |
1,118,828 |
| William Anderson Wittekind | 10% Owner |
Jul 02 '24 |
Sale |
1.54 |
34,553 |
53,212 |
1,084,275 |
| William Anderson Wittekind | 10% Owner |
Jun 26 '24 |
Sale |
1.57 |
50,000 |
78,500 |
1,193,499 |
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):